Marksans Pharma (MARKSANS) Fundamentals 2026 — P/E 26.1x, Revenue Analysis | SniperIQ
Marksans Pharma (MARKSANS) is a India-listed Healthcare company in Drug Manufacturers - General with a market capitalization of ₹10,893 Crore, trading at ₹240.90 on the BSE. This SniperIQ fundamentals page covers Marksans Pharma's valuation (P/E 26.1x, P/B 3.6x), profitability (net margin 14.2%), revenue (₹2,951 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Marksans Pharma's market cap?
Marksans Pharma (MARKSANS) has a market capitalization of approximately ₹10,893 Crore, trading at ₹240.90 on the BSE. Market cap moves with the live share price.
What is Marksans Pharma's P/E ratio?
Marksans Pharma's trailing twelve-month P/E ratio is 26.1x, with a price-to-book (P/B) of 3.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Marksans Pharma?
Marksans Pharma runs a net profit margin of 14.2%, a gross margin of 47.7%, and an operating margin of 17.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Marksans Pharma generate?
Marksans Pharma reported revenue of ₹2,951 Crore for fiscal year 2026, with net income of ₹418 Crore and earnings per share (EPS) of 9.22. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Marksans Pharma pay a dividend?
Marksans Pharma offers a trailing dividend yield of about 0.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Marksans Pharma financially healthy?
Marksans Pharma carries a debt-to-equity ratio of 0.11x and a current ratio of 5.17x, with a market beta of 1.07. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Marksans Pharma a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Marksans Pharma (MARKSANS) the key facts are: market cap ₹10,893 Crore, P/E 26.1x, revenue ₹2,951 Crore, 52-week range 157.25-276.15. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Marksans Pharma's full fundamentals live
Get Marksans Pharma's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.